CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice

• Main Authors: Matthew Riopel (Author), Melanie Vassallo (Author), Erik Ehinger (Author), Jennifer Pattison (Author), Karen Bowden (Author), Holger Winkels (Author), Maria Wilson (Author), Ron de Jong (Author), Sanjay Patel (Author), Deepika Balakrishna (Author), James Bilakovics (Author), Andrea Fanjul (Author), Artur Plonowski (Author), Christopher J. Larson (Author), Klaus Ley (Author), Pedro Cabrales (Author), Joseph L. Witztum (Author), Jerrold M. Olefsky (Author), Yun Sok Lee (Author)
• Format: Book
• Published: Elsevier, 2019-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Atherosclerosis is a major cause of cardiovascular disease. Monocyte-endothelial cell interactions are partly mediated by expression of monocyte CX3CR1 and endothelial cell fractalkine (CX3CL1). Interrupting the interaction between this ligand-receptor pair should reduce monocyte binding...